The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Higher Risk of Venous Thrombosis During Early Use of Oral Contraceptives in Women With Inherited Clotting Defects
Abstract
BACKGROUND: Results of recent studies show that the risk for venous thrombosis is highest during initial oral contraceptive use. This suggests a subgroup of females who are at immediate risk of thrombosis when exposed to oral contraceptives. OBJECTIVE: To determine whether women with inherited clotting defects who use oral contraceptives develop venous thrombosis at an earlier stage than do those without inherited clotting defects. METHODS: Analysis of the data from the Leiden Thrombophilia Study, a population-based case-control study with data on duration of oral contraceptive use and recently detected genetic coagulation disorders. Patients had a first episode of objectively proven deep vein thrombosis. Patients and controls were considered thrombophilic when they had protein C deficiency, protein S deficiency, antithrombin deficiency, factor V Leiden mutation, or prothrombin 20210 A mutation. RESULTS: Risk of developing deep vein thrombosis was greatest in the first 6 months and the first year of oral contraceptive use. Compared with prolonged use, the risk of developing deep vein thrombosis was 3-fold higher in the first 6 months of use (95% confidence interval [CI], 0.6-14.8) and 2-fold higher in the first year of use (95% CI, 0.6-6.1). Patients who developed venous thrombosis in the early periods of use were more often thrombophilic. Among women with thrombophilia, the risk of developing deep vein thrombosis during the first 6 months of oral contraceptive use (compared with prolonged use) was increased 19-fold (95% CI, 1.9-175.7), and in the first year of use, it was increased 11-fold (95% CI, 2.1-57.3). CONCLUSIONS: Women with inherited clotting defects who use oral contraceptives develop venous thrombosis not only more often but also sooner than do those without inherited clotting defects. Venous thrombosis in the first period of oral contraceptive use might indicate the presence of an inherited clotting defect.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The most common clinical presentation of estrogen-related thrombosis is venous thromboembolism (VTE) of the deep veins of the legs or pulmonary vessels, usually within the first few months of use.”
From Estrogen and thrombosis: a bench to bedside review (2020) · cites this paper as [101]
In the citing paper
“Data from the population-based case-control Leiden Thrombophilia Study showed that the risk of developing VTE was greatest in the first 6 months of CHC use.”
From Estrogen and thrombosis: a bench to bedside review (2020) · cites this paper as [101]
Citations
Cites
Mutation in blood coagulation factor V associated with resistance to activated protein C
Bertina, R. M., Koeleman, B. P. C., Koster, T., Rosendaal, F. R., Dirven, R. J., de Ronde, H., van der Velden, P. A., & Reitsma, P. H. (1994) · Nature · doi:10.1038/369064a0 · Cited by 3,769
Self-citationPoort, S., Rosendaal, F. R., Reitsma, P. H., & Bertina, R. M. (1996) · Blood · doi:10.1182/blood.v88.10.3698.bloodjournal88103698 · Cited by 3,045
Self-citationKoster, T., Vandenbroucke, J. P., Rosendaal, F. R., de Ronde, H., Briët, E., & Bertina, R. M. (1993) · The Lancet · doi:10.1016/s0140-6736(05)80081-9 · Cited by 1,236
Self-citationVandenbroucke, J. P., Koster, T., Rosendaal, F. R., Briët, E., Reitsma, P. H., & Bertina, R. M. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90286-0 · Cited by 1,063
Self-citationRosendaal, F. R., Koster, T., Vandenbroucke, J. P., & Reitsma, P. H. (1995) · Blood · doi:10.1182/blood.v85.6.1504.bloodjournal8561504 · Cited by 999
Self-citationSpitzer, W. O., Lewis, M. A., Heinemann, L. A. J., Thorogood, M., & MacRae, K. D. (1996) · BMJ · doi:10.1136/bmj.312.7023.83 · Cited by 590
Bloemenkamp, K. W. M., Helmerhorst, F. M., Rosendaal, F. R., Vandenbroucke, J. P., & Buller, H. R. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91929-5 · Cited by 576
Self-citationInvestigation of relation between use of oral contraceptives and thromboembolic disease.
Vessey, M. P., & Doll, R. (1968) · BMJ · doi:10.1136/bmj.2.5599.199 · Cited by 471
Vessey, M. P., & Doll, R. (1969) · BMJ · doi:10.1136/bmj.2.5658.651 · Cited by 403
Koster, T., Rosendaal, F. R., Briët, E., van der Meer, F. J. M., Colly, L. P., Trienekens, P., Poort, S., Reitsma, P. H., & Vandenbroucke, J. P. (1995) · Blood · doi:10.1182/blood.v85.10.2756.bloodjournal85102756 · Cited by 362
Self-citation
Cited by
Sorted by citations
U.S. Medical Eligibility Criteria for Contraceptive Use, 2016
Curtis, K. M., Tepper, N. K., Jatlaoui, T. C., Berry-Bibee, E., Horton, L. G., Zapata, L. B., Simmons, K. B., Pagano, H. P., Jamieson, D. J., & Whiteman, M. K. (2016) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6503a1 · Cited by 1,456
Practice Bulletin No. 183: postpartum hemorrhage
(2017) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002351 · Cited by 1,406
Kyrle, P. A., & Eichinger, S. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71880-8 · Cited by 625
Oral Contraceptives and the Risk of Venous Thrombosis
Vandenbroucke, J. P., Rosing, J., Bloemenkamp, K. W. M., Middeldorp, S., Helmerhorst, F. M., Bouma, B. N., & Rosendaal, F. R. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105173442007 · Cited by 580
Self-citationWu, O., Robertson, L., Twaddle, S., Lowe, G. D. O., Clark, P., Greaves, M., Walker, I. D., Langhorne, P., Brenkel, I., Regan, L., et al. (2006) · Health Technology Assessment · doi:10.3310/hta10110 · Cited by 489
Metadata
- Authors
- Bloemenkamp, K. W. M., Rosendaal, F. R., Helmerhorst, F. M., & Vandenbroucke, J. P.
- Affiliations
- Leiden University Medical Center (NL)
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2000-01-10
- Volume
- 160
- Issue
- 1
- Pages
- 49
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2163417915
- Cited by
- 213
- References
- 27
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 9 · 2023: 2 · 2022: 6 · 2021: 6 · 2020: 3 · 2019: 3 · 2018: 2 · 2017: 10 · 2016: 8 · 2015: 6 · 2014: 5 · 2013: 6 · 2012: 5
- FWCI
- 9.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- venous thrombosis, deep vein thrombosis, oral contraceptives, thrombophilia, duration of contraceptive use, protein C deficiency, protein S deficiency, antithrombin deficiency, factor V Leiden, prothrombin G20210A
- MeSH terms
- Adolescent, Adult, Blood Coagulation Disorders, Contraceptives, Oral, Female, Humans, Middle Aged, Risk, Risk Factors, Time Factors, Case-Control Studies, Venous Thrombosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review